Concepedia

Naloxone can improve the anti-tumor immunity by reducing the CD4+CD25+Foxp3+ regulatory T cells in BALB/c mice

Agheel Tabar Molla Hassan, Zuhair Mohammad Hassan, Seyed Mohammad Moazzeni, Ali Mostafaie, Shahram Shahabi, Massoumeh Ebtekar, Seyed Mahmoud Hashemi

International Immunopharmacology · 2009 · 27 citations · 25 references

DOI

Concepts

References

25

Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity

Jun Shimizu, Sayuri Yamazaki, Shimon Sakaguchi · The Journal of Immunology · 1999 · 1.5K citations · Full text

, , +17

CD91 Is a Common Receptor for Heat Shock Proteins gp96, hsp90, hsp70, and Calreticulin

Sreyashi Basu, Robert Binder, Thirumalai R. Ramalingam et al. · Immunity · 2001 · 1.1K citations · Full text

, , +6

Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

Shin Onizuka, Isao Tawara, Jun Shimizu et al. · PubMed · 1999 · 1.1K citations

, , +15

Immunotherapy of Tumors with Autologous Tumor-Derived Heat Shock Protein Preparations

Yasuaki Tamura, Ping Peng, Kang Liu et al. · Science · 1997 · 681 citations

, , +17

Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens

Denise Golgher, Emma Jones, Fiona Powrie et al. · European Journal of Immunology · 2002 · 280 citations · Full text

, , +17